YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development

Trastuzumab-emtansine (T-DM1) is a therapeutic agent molecularly targeting human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), and it is especially effective for MBC with resistance to trastuzumab. Although several reports have described T-DM1 resistance, few hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujihara, Miwa, Shien, Tadahiko, Shien, Kazuhiko, Suzawa, Ken, Takeda, Tatsuaki, Zhu, Yidan, Mamori, Tomoka, Otani, Yusuke, Yoshioka, Ryo, Uno, Maya, Suzuki, Yoko, Abe, Yuko, Hatono, Minami, Tsukioki, Takahiro, Takahashi, Yuko, Kochi, Mariko, Iwamoto, Takayuki, Taira, Naruto, Doihara, Hiroyoshi, Toyooka, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657782/
https://www.ncbi.nlm.nih.gov/pubmed/34884609
http://dx.doi.org/10.3390/ijms222312809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657782/
https://www.ncbi.nlm.nih.gov/pubmed/34884609
http://dx.doi.org/10.3390/ijms222312809

Ejemplares similares